The Filing Desk

Actinium Pharmaceuticals vs Lisata Therapeutics

Actinium Pharmaceuticals ATNM · Lisata Therapeutics LSTA · Pharmaceuticals

Lisata Therapeutics reported revenue of $0 million in fiscal 2025, 2.0 times Actinium Pharmaceuticals' $0 million in fiscal 2025. Actinium Pharmaceuticals had an operating margin of -40274.4%, against -10711.2% at Lisata Therapeutics. Free cash flow was −$25 million at Actinium Pharmaceuticals and −$16 million at Lisata Therapeutics.

Side by side

Actinium PharmaceuticalsLisata Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$0M
Revenue growth—−83.0%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−40,274.4%−10,711.2%
Net margin−37,652.2%−9,756.5%
Free cash flow−$25M−$16M
Free cash flow margin−27,426.7%−9,398.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.7%4.3%
Last close$1.07$0.91
P/E at the last close3.2×—
Insider trades, last 12 months——
Piotroski F-score—1 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Actinium PharmaceuticalsLisata Therapeutics
Operating margin
Percent of revenue
Actinium PharmaceuticalsLisata Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Actinium PharmaceuticalsLisata Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Actinium Pharmaceuticals and Lisata Therapeutics pages.